The Committee for Medicinal Products for Human Use (CHMP) of the EMA grants Emergent BioSolutions’ (NYSE:EBS) chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, PRIority MEdicines, or PRIME, designation.
PRIME Designation allows for frequent and early
interactions with the EMA aimed at supporting accelerated evaluation and
approval.
The company expects to initiate a pivotal trial in 2020.
https://seekingalpha.com/news/3504938-emergent-bio-receives-prime-designation-chikungunya-virus-vlp-vaccine-candidate
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.